(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.63%) $83.25
(0.34%) $1.763
(0.21%) $2 403.00
(1.13%) $28.70
(-1.15%) $943.50
(-0.08%) $0.939
(-0.22%) $11.02
(0.54%) $0.808
(-0.93%) $93.02
Live Chart Being Loaded With Signals
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage...
Stats | |
---|---|
Today's Volume | 585 166 |
Average Volume | 707 323 |
Market Cap | 424.20M |
EPS | $0 ( 2024-02-27 ) |
Last Dividend | $0.117 ( 2004-10-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.360 |
ATR14 | $0.00100 (0.16%) |
Volume Correlation
Opthea Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Opthea Ltd Correlation - Currency/Commodity
Opthea Ltd Financials
Annual | 2023 |
Revenue: | $161 163 |
Gross Profit: | $-89 309.00 (-55.42 %) |
EPS: | $-0.450 |
Q2 | 2023 |
Revenue: | $93 181.00 |
Gross Profit: | $14 798.00 (15.88 %) |
EPS: | $-0.250 |
Q4 | 2023 |
Revenue: | $83 337.00 |
Gross Profit: | $83 337.00 (100.00 %) |
EPS: | $-0.200 |
Q2 | 2023 |
Revenue: | $77 793.00 |
Gross Profit: | $77 793.00 (100.00 %) |
EPS: | $-0.230 |
Financial Reports:
No articles found.
Opthea Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.117 | 2004-10-11 |
Last Dividend | $0.117 | 2004-10-11 |
Next Dividend | $0 | N/A |
Payout Date | 2004-11-01 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.117 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0.0275 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WOW.AX | Ex Dividend Junior | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
FAR.AX | No Dividend Player | 2023-08-23 | Sporadic | 0 | 0.00% | |
PIC.AX | Ex Dividend Junior | 2023-09-26 | Semi-Annually | 0 | 0.00% | |
APE.AX | Ex Dividend Junior | 2023-09-01 | Annually | 0 | 0.00% | |
HZN.AX | Ex Dividend Knight | 2023-10-17 | Annually | 0 | 0.00% | |
RMS.AX | Ex Dividend Junior | 2023-09-14 | Sporadic | 0 | 0.00% | |
CAJ.AX | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
LSF.AX | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
SXL.AX | Ex Dividend Knight | 2023-09-01 | Annually | 0 | 0.00% | |
CSR.AX | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1 383.77 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.467 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 8.77 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.00 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.82 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000780 | -1.500 | 9.99 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -8.08 | 1.000 | -4.10 | -4.10 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.153 | -0.306 | [0 - 20] |
debtEquityRatioTTM | -0.00277 | -1.500 | -0.0111 | 0.0166 | [0 - 2.5] |
grossProfitMarginTTM | 0.556 | 1.000 | 4.07 | 4.07 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1 413.43 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 397.12 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00106 | 0.800 | -3.33 | -2.66 | [0.5 - 2] |
Total Score | 0.0275 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.735 | 1.000 | -0.276 | 0 | [1 - 100] |
returnOnEquityTTM | 8.77 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.306 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.306 | 2.00 | -0.102 | -0.204 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0195 | 1.500 | -3.20 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1 027.63 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -0.549 |
Opthea Ltd
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators